Target intelligence / Profile preview

Kit tyrosine-protein kinase receptor (KIT)

Target
KIT
Molecular classification
Receptor tyrosine kinase (class III; type III RTK), Enzyme (kinase), Cell surface receptor
01

Overview

Kit tyrosine-protein kinase receptor (commonly known as c-KIT or CD117) is a transmembrane receptor tyrosine kinase of the class III family, structurally composed of five extracellular immunoglobulin-like domains, a transmembrane segment, a juxtamembrane regulatory region, and an intracellular split tyrosine kinase domain. Its physiological ligand is stem cell factor (SCF, KITLG), and signaling through KIT is essential for hematopoietic progenitor cell survival, proliferation, gametogenesis, melanocyte development, and gastrointestinal pacemaker cell function. KIT is a critical marker for hematopoietic and other somatic stem cells, and gain-of-function mutations drive various cancers, notably gastrointestinal stromal tumors and acute myelogenous leukemia, where KIT inhibitors form a central therapy. KIT is broadly implicated in stem cell biology, immune cell regulation, and multiple disease processes tied to deregulated cell proliferation and survival.

Other names
CD117c-KITStem cell factor receptorSCFRTyrosine-protein kinase KITProto-oncogene c-Kit
02

Mechanism of action

Small molecule tyrosine kinase inhibitors that compete with ATP for binding to the intracellular kinase domain, thereby blocking downstream signaling and oncogenic cell proliferation

03

Biological functions

Signal transductionCell proliferationCell survival/apoptosis regulationCell migrationHematopoiesis (blood cell formation)Gametogenesis (including oogenesis, spermatogenesis)Mast cell development and functionMelanogenesis (pigmentation)Stem cell maintenance
04

Disease associations

Cancer (e.g., gastrointestinal stromal tumor, acute myelogenous leukemia, mastocytoma, melanoma)Pigmentation disorders (vitiligo, piebaldism)Infertility (germ cell development defects)Cardiovascular disease (through interstitial cells of Cajal dysfunction)
05

Safety considerations

Secondary resistance due to point mutations in KITOff-tumor effects, especially on hematopoietic progenitors and melanocytes (can cause cytopenias, depigmentation, infertility)Drug interactions with multi-targeted kinase inhibitors
06

Interacting drugs

6 more in the full profile.

07

Biomarkers

CD117/c-KIT immunoreactivity (for tumor diagnosis, especially gastrointestinal stromal tumor and some leukemias)KIT mutation status (for predicting targeted therapy response and resistance)

Beyond the preview

Go deeper on Kit tyrosine-protein kinase receptor (KIT).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Kit tyrosine-protein kinase receptor (KIT).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call